Masimo (MASI)
(Delayed Data from NSDQ)
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
Why Is Masimo (MASI) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
Masimo's (MASI) SedLine Receives FDA's Pediatric Indication
by Zacks Equity Research
The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo (MASI) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Study Favors Masimo's (MASI) SedLine for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.
Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable
by Zacks Equity Research
Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.
Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings
by Zacks Equity Research
The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Masimo (MASI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study
by Zacks Equity Research
Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.